èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã BioXcel Therapeutics, Inc. ã¯ãç±³åœã§ç¥çµç§åŠãšå
ç«è
«çåŠã®åéã§äººå·¥ç¥èœããŒã¹ã®å»è¬åéçºã«æ³šåããŠããŸããå瀟ã¯ãç¥çµçŸæ£ã粟ç¥çŸæ£ã«èµ·å ããèå¥®ã®æ²»çãç®çãšããã¢ãã¬ããªã³å容äœäœåè¬ãã¯ã¹ã¡ããããžã³ã®èäžèèè£œå€ BXCL501 ãšãåç«è
ºãããèµèãããåºåœ¢è
«çã®æ²»çãç®çãšããå
ç«æŽ»æ§åå€ BXCL701 ã®éçºã«æºãã£ãŠããŸããBioXcel Therapeutics, Inc. ã¯ãã¢ã«ã³ãŒã«ãè¬ç©ä¹±çšé害ã«é¢é£ããå¿çå€å·åŸã¹ãã¬ã¹é害ã«èŠããæ£è
ã®ããã«ãã³ããã«ããå· VA ãã«ã¹ã±ã¢ ã·ã¹ãã ããã³ã€ã§ãŒã«å€§åŠå»åŠéšãšææºããŠããŸããå瀟㯠2017 幎ã«èšç«ãããã³ããã«ããå·ãã¥ãŒãã€ãã³ã«æ¬ç€Ÿã眮ããŠããŸãã